期刊文献+

FOXA1表达在乳腺癌分子亚型中的诊断及预后意义 被引量:3

Diagnostic and prognostic significance of FOXA1 expression in molecular subtypes of breast invasive ductal carcinomas
原文传递
导出
摘要 目的 观察乳腺浸润性导管癌中FOXA1的表达,以及在各分子亚型中的表达及其诊断、预后意义.方法 收集乳腺浸润性导管癌213例,应用免疫组化方法检测FOXA1、Ki67在各分子亚型中的表达情况,检测CK5/6、CK14用于区分正常乳腺样型和基底细胞样型.结果 213例乳腺浸润性导管癌中150例(70.4%)见FOXA1表达,FOXA1的表达与ER、PR呈正相关,与组织学分级、Nottingham预后指数、p53、Ki67呈负相关.FOXA1表达在Luminal亚型与非Luminal亚型之间表达有差异性.在Luminal亚型中,FOXA1的表达与组织学分级、PR、NPI和Ki67、Luminal A亚型有相关性.在预后方面:FOXA1的表达与长的无病生存期、总生存期有关.结论 在乳腺浸润性导管癌中FOXA1的表达与预后较好相关,FOXA1表达有可能被用于鉴别Luminal A亚型,亦可应用FOXA1在低风险乳腺癌中的预后意义来选择治疗方法. Objective To investigate the expression of FOXA1 in breast invasive ductal carcinomas, observe its expression in all molecular subtypes of breast invasive ductal carcinomas and understand its diagnostic and prognostic significance. Methods Tissue specimens were obtained from 213 cases of breast invasive ductal carcinoma (IDC) and their expressions of FOXA1 and Ki67 detected by immunohistochemistry. And the expressions of CK5/6 and CK14 were detected to distinguish between normal breast-like subtype and basal-like subtype. Results The expression of FOXA1 was observed in 150 cases (70. 4%). It correlated positively with ER and PR. But there was a negative correlation with histological grade, Nottingham prognostic index, p53 and Ki67. The expression of FOXA1 had difference between luminal and non-luminal subtypes. In luminal subtype, the expression of FOXA1 was associated with histological grade, PR, NPI, Ki67 and A subtype. In terms of prognosis, the expression of FOXA1 predicted a long disease-free survival and overall survival. Conclusion The expression of FOXA1 is associated with a good prognosis. FOXA1 is a promising candidate for clinical identification of luminal A subtype. Prognostic analysis of FOXA1 in low-risk breast cancers may prove to be useful in clinical treatment decision-making.
出处 《中华医学杂志》 CAS CSCD 北大核心 2010年第20期1403-1407,共5页 National Medical Journal of China
基金 国家自然科学基金(30872519) 教育部长江学者和创新团队计划(TRT0743)
关键词 乳腺肿瘤 分子亚型 FOXA1 预后 Breast carcinoma Molecular subtype FOXA1 Prognosis
  • 相关文献

参考文献20

  • 1Badve S,Turbin D,Thorat MA,et al FOXA1 expression in breast cancel-correlation with luminal subtype A and survival.Clin Cancer Res,2007,13:4415-4421.
  • 2Sorlie T,Tibshirani R,Parker J,et al.Repeated observation of breast tumor subtypes in independent gene expression data sets.Proc Natl Acad Sci U S A.2003,100:8418-8423.
  • 3Nakshatri H,Badve S.FOXA1 as a therapeutic target for breast cancer.Expert Opin Ther Targets.2007,11:507-514.
  • 4Tavassoli FA,Devilee P.The WHO classification of tumors of the breast and female genital organs(M).Editors IARC Press,Lyon.2003:10-112.
  • 5Habashy HO,Powe DG,Rakha EA,et al.Forkhead-box Al (FOXA1) expression in breast cancer and its prognostic significance.Eur J Cancer,2008,44:1541-1551.
  • 6Thorat MA,Marchio C,Morimiya A,et al.Forkhead box Al expression in breast cancer is associated with luminal subtype and good prognosis.J Clin Pathol,2008,61:327-332.
  • 7Wolf AC,Hammond ME,Schwartz JN,et al.American Society of Clinical Oncology/College of American Pathologists guideline recommendation for human epidermal growth factor 2 testing in breast cancer.Arch Pathol Lab Med,2007,131:18-43.
  • 8Perou CM,Sorlie T,Eisen MB,et al.Molecular portraits of human breast tumours.Nature,2000,406:747-752.
  • 9Nielsen TO,Hsu FD,Jensen K,et al.Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res,2004,10:5367-5374.
  • 10Jumppanen M,Gruvberger-Saal S,Kauraniemi P,et al.Basal-like phenotype is not associated with patient survival in estrogenreceptor-negative breast cancers.Breast Cancer Res.2007,9:R16.

二级参考文献62

共引文献27

同被引文献39

  • 1Su ZZ, Lee SG, Emdad L, et al. Cloning and characterization of SARI (suppressor of AP-1, regulated by IFN). Proc Nat Acad Sci USA, 2008, 105 : 20906-20911.
  • 2Dash R, Su ZZ, Lee SG, et al. Inhibition of AP-1 by SARI negatively regulates transformation progression mediated by CCN1. Oncogene, 2010, 29: 4412-4423.
  • 3Ma H, Liang X, Chen Y, et al. Decreased expression of BATF2 is associated with a poor prognosis in hepatocellular carcinoma. Int J Cancer, 2011, 128: 771-777.
  • 4Mo FE, Muntean AG, Chen CC, et al. CYR61 ( CCN1 ) is essential for placental development and vascular integrity. Mol Cell Biol, 2002, 22: 8709-8720.
  • 5Kok SH, Chang HH, Tsai JY, et al. Expression of Cyr61 (CCN1) in human oral squamous cell carcinoma: an independent marker for poor prognosis. Head Neck, 2010, 32: 1665-1673.
  • 6Haque I, Mehta S, Majumder M, et al. Cyr61/CCN1 signaling is critical for epithelial-mesenchymal transition and stemness and promotes pancreatic carcinogenesis. Mol Cancer, 2011, 10: 8.
  • 7Tan TW, Yang WH, Lin YT, et al. Cyr61 increases migration and MMP-13 expression via alphavbeta3 integrin, FAK, ERK and AP-l-dependent pathway in human chondrosarcoma cells. Carcinogenesis, 2009, 30: 258-268.
  • 8You JJ, Yang CM, Chen MS, et al. Regulation of Cyr61/CCN1 expression by hypoxia through cooperation of c-Jun/AP-1 and HIF- 1α in retinal vascular endothelial cells. Exp Eye Res, 2010, 91: 825 -836.
  • 9Gery S, Xie D, Yin D, et al. Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells. Clin Cancer Res, 2005, 11:7243-7254.
  • 10Rouzier R, Ouzier R, Rajan R, et al. Microtubule associated protein tau:a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A,2005,102:8315-8320.

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部